Natixis Advisors LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,131 shares of the company's stock, valued at approximately $469,000.
Other large investors have also modified their holdings of the company. Assetmark Inc. bought a new stake in Cellebrite DI in the 1st quarter valued at $33,000. Catalyst Capital Advisors LLC bought a new stake in Cellebrite DI in the 1st quarter valued at $51,000. Gen Wealth Partners Inc bought a new stake in Cellebrite DI in the 4th quarter valued at $85,000. NewEdge Advisors LLC raised its stake in shares of Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after buying an additional 3,352 shares in the last quarter. Finally, Sigma Planning Corp acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $233,000. 45.88% of the stock is owned by institutional investors.
Analyst Ratings Changes
CLBT has been the subject of a number of recent analyst reports. Lake Street Capital dropped their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday. Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. dropped their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Cellebrite DI has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.
View Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Stock Up 4.2%
NASDAQ:CLBT traded up $0.64 during mid-day trading on Friday, reaching $15.93. 3,073,875 shares of the company were exchanged, compared to its average volume of 1,640,364. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The company has a fifty day moving average of $15.00 and a 200 day moving average of $17.88. The stock has a market cap of $3.82 billion, a PE ratio of -16.60, a PEG ratio of 2.82 and a beta of 1.27.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. On average, equities research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access